Trevi Therapeutics (NASDAQ:TRVI) Earns Buy Rating from D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI - Free Report) in a research report released on Monday morning,Benzinga reports. They currently have a $21.00 target price on the stock.

Several other analysts have also recently weighed in on TRVI. Oppenheimer lifted their price target on Trevi Therapeutics from $12.00 to $20.00 and gave the stock an "outperform" rating in a report on Tuesday, March 11th. HC Wainwright started coverage on shares of Trevi Therapeutics in a report on Wednesday, May 28th. They issued a "buy" rating and a $21.00 price objective for the company. Raymond James raised shares of Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and raised their target price for the stock from $9.00 to $29.00 in a report on Monday, March 10th. Needham & Company LLC reiterated a "buy" rating and issued a $24.00 price target on shares of Trevi Therapeutics in a research report on Tuesday, May 20th. Finally, B. Riley reiterated a "buy" rating and issued a $20.00 price target (up from $11.00) on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Seven investment analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $18.63.

Trevi Therapeutics Stock Up 4.3%

Shares of NASDAQ TRVI traded up $0.28 during mid-day trading on Monday, reaching $6.86. 1,534,210 shares of the company were exchanged, compared to its average volume of 1,302,783. The stock has a market capitalization of $685.27 million, a P/E ratio of -15.59 and a beta of 0.59. The company's 50-day simple moving average is $6.23 and its 200-day simple moving average is $4.93. Trevi Therapeutics has a twelve month low of $2.30 and a twelve month high of $7.48.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.04. As a group, equities research analysts expect that Trevi Therapeutics will post -0.49 EPS for the current year.

Insider Buying and Selling at Trevi Therapeutics

In other news, CEO Jennifer L. Good sold 5,263 shares of the firm's stock in a transaction that occurred on Friday, March 21st. The shares were sold at an average price of $6.58, for a total value of $34,630.54. Following the sale, the chief executive officer now directly owns 213,313 shares in the company, valued at approximately $1,403,599.54. This trade represents a 2.41% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Farrell Simon sold 81,313 shares of the company's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $6.75, for a total transaction of $548,862.75. Following the transaction, the insider now owns 76,900 shares of the company's stock, valued at approximately $519,075. This represents a 51.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 18.30% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Point72 Asset Management L.P. bought a new position in Trevi Therapeutics in the fourth quarter valued at about $17,099,000. Octagon Capital Advisors LP bought a new position in Trevi Therapeutics in the 1st quarter valued at approximately $20,895,000. Frazier Life Sciences Management L.P. boosted its position in Trevi Therapeutics by 44.5% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 10,664,774 shares of the company's stock worth $43,939,000 after buying an additional 3,283,684 shares during the period. Armistice Capital LLC bought a new stake in Trevi Therapeutics during the 1st quarter worth approximately $18,795,000. Finally, Woodline Partners LP grew its holdings in Trevi Therapeutics by 429.9% during the 4th quarter. Woodline Partners LP now owns 3,212,597 shares of the company's stock worth $13,236,000 after acquiring an additional 2,606,370 shares during the last quarter. 95.76% of the stock is currently owned by institutional investors and hedge funds.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.